Tag: gastrointestinal stromal tumor market outlook

Uncover key drivers, emerging technologies, and competitive movements shaping the gastrointestinal stromal tumor market from 2026–2035 with trusted insights from The Business Research Company

How much is the Gastrointestinal Stromal Tumor Market valued at in 2026, and what valuation is forecast for 2030?

The gastrointestinal stromal tumor market size has recently shown strong expansion. It is anticipated to increase from $1.36 billion in 2025 to $1.46 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.9%. During the past period, this growth was primarily due to the approval of imatinib therapy, advancements in tumor classification, the expansion of oncology care centers, a rise in awareness regarding rare gi tumors, and the availability of surgical interventions.

The market size for gastrointestinal stromal tumors is expected to experience substantial growth in the upcoming years. It is projected to expand to $1.98 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.0%. This anticipated growth can be attributed to the development of advanced targeted therapies, an increase in precision diagnostics, a rise in clinical trials, the expansion of personalized cancer treatment options, and improved survival outcomes for patients. Throughout the forecast period, significant trends include the increasing use of targeted tyrosine kinase inhibitors, a greater focus on molecular tumor profiling, the widespread adoption of precision oncology approaches, an increase in combined surgical and drug therapies, and enhanced long-term disease management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

What Drivers Are Influencing The Growth Of The Gastrointestinal Stromal Tumor Market?

The increasing occurrence of stomach cancer is projected to stimulate the expansion of the gastrointestinal stromal tumor market in the future. This condition, stomach cancer, involves the uncontrolled proliferation of cancerous cells within the stomach’s inner lining. Although gastrointestinal stromal tumors (GISTs) can manifest in the stomach, they are recognized as separate entities from stomach cancer. It has been noted that patients with GISTs face an increased risk of developing other cancers, including small bowel adenocarcinoma, particularly when two distinct tumors collide and merge into one. As an illustration, the American Cancer Society, a professional organization based in the US, reported in January 2024 that approximately 26,890 fresh diagnoses of stomach cancer and 10,880 fatalities are projected in the U.S. for 2024, representing 1.5% of all new cancer diagnoses. Consequently, the rising prevalence of stomach cancer is fueling the expansion of the gastrointestinal stromal tumor market.

What Segments Are Included Within The Gastrointestinal Stromal Tumor Market?

The gastrointestinal stromal tumor market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types

2) By Indication: Stomach, Small Intestine, Others Indications

3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users

Subsegments:

1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens

2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents

3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies

Which Trends Are Expected To Influence The Gastrointestinal Stromal Tumor Market In The Upcoming Years?

Major companies operating within the gastrointestinal stromal tumor market are actively developing novel drugs, such as signal transduction and targeted therapy, with the aim of enhancing treatment effectiveness, overcoming resistance to current therapies, and addressing unmet clinical requirements. Signal transduction and targeted therapy are approaches designed to inhibit or alter specific cellular signaling pathways crucial for tumor growth and survival. For example, in November 2025, Ascentage Pharma Group International Inc., a commercial-stage biopharmaceutical firm based in China, revealed the publication of Phase Ib clinical data for olverembatinib (HQP1351) in Signal Transduction and Targeted Therapy. This report highlighted promising efficacy and safety results in SDH-deficient gastrointestinal stromal tumors (GIST) and identified a novel antitumor mechanism involving lipid metabolism modulation.

Who Are The Major Companies Operating In The Gastrointestinal Stromal Tumor Market?

Major companies operating in the gastrointestinal stromal tumor market are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Gastrointestinal Stromal Tumor Market?

North America was the largest region in the gastrointestinal stromal tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gastrointestinal Stromal Tumor Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Stromal Tumor Market 2026, By The Business Research Company

Gastrointestinal Endoscopy Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-endoscopy-global-market-report

Gastric Cancer Diagnostic Procedure Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Germ Cell Tumor Market Report 2026

https://www.thebusinessresearchcompany.com/report/germ-cell-tumor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Gastrointestinal Stromal Tumor Market Expected To Grow In Terms Of Size?

In recent times, the market for gastrointestinal stromal tumors has seen significant growth. This market is projected to increase from $1.28 billion in 2024 to $1.36 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%. The noticeable growth during the previous period is attributable to factors such as increased cognizance and early diagnosis, the development of targeted treatments, advanced surgical techniques, the creation of personalized medical approaches, and improvements in supportive care.

In the coming years, robust expansion is predicted for the gastrointestinal stromal tumor market. With a Compound Annual Growth Rate (CAGR) of 7.5%, projections forecast a value of $1.82 billion by 2029. Factors contributing to this positive outlook during the forecast period encompass ongoing investigation and drug innovation, an escalation in patient-focused healthcare, the incorporation of precision medicine in medical practice, widened access to targeted treatments, and the broadening of genomic profiling abilities. The forecast period is also set to witness significant trends such as increased cooperation in research and development, advancements in diagnostic technology, collective research and clinical examinations, amplified attention on early detection and diagnosis, and the investigation into combination therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

What Are The Primary Factors Supporting The Gastrointestinal Stromal Tumor Market Expansion?

The rise in stomach cancer cases is anticipated to stimulate the advancement of the gastrointestinal stromal tumor market. Stomach cancer is characterized by the unchecked proliferation and growth of malignant cells on the stomach’s inner lining. Although gastrointestinal stromal tumors (GISTs) can be found in the stomach, they are not the same as stomach cancer. Patients with GISTs have shown an elevated risk of developing other cancers, such as small bowel adenocarcinoma, when two distinct tumors converge into one. As an example, the American Cancer Society, an experienced organization based in the United States, foresaw approximately 26,890 stomach cancer cases and 10,880 fatalities in the U.S. in January 2024, contributing to 1.5% of all new cancer diagnoses. Consequently, the mounting incidence of stomach cancer is fueling the growth of the gastrointestinal stromal tumor market.

Which Segmentation Categories Are Highlighted In The Gastrointestinal Stromal Tumor Market Analysis?

The gastrointestinal stromal tumormarket covered in this report is segmented –

1) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types

2) By Indication: Stomach; Small Intestine; Others Indications

3) By End-User: Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End-Users

Subsegments:

1) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy Regimens

2) By Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Agents

3) By Other Treatment Types: Surgery; Radiation Therapy; Clinical Trials For Novel Therapies

Which Trends Are Likely To Redefine Growth Paths In The Gastrointestinal Stromal Tumor Market?

Leading businesses in the gastrointestinal stromal tumor market are producing innovative drugs like QINLOCK (Ripretinib) to appeal to a wider consumer base, raise their sales, and grow their profits. QINLOCK (Ripretinib) is a prescribed medication for advanced gastrointestinal stromal tumor (GIST). For instance, the US Food and Drug Administration (FDA), a federal agency in the US, noted in January 2024, that there were an increase in CDER novel drug approvals from 37 in 2022 to 55 in 2023. Furthermore, out of the 55 new drugs approved in 2023, CDER recognized 20 (or 36%) as being the first of their kind.

Which Organizations Are At The Forefront Of The Gastrointestinal Stromal Tumor Market?

Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Gastrointestinal Stromal Tumor Market?

North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Stromal Tumor Market 2025, By The Business Research Company

Tumor Ablation Therapy Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

Tumor Embolization Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

Cancer Tumor Profiling Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Gastrointestinal Stromal Tumor Market?

The gastrointestinal stromal tumor market has experienced substantial expansion in recent years. This market is projected to grow from $1.28 billion in 2024 to $1.36 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.7%. The historical growth can be ascribed to elements like heightened awareness and early diagnosis, the advent of targeted therapies, advancements in surgical techniques, the evolution of personalized medicine, and enhancements in supportive care.

The market for gastrointestinal stromal tumors is projected to experience substantial expansion over the upcoming years. This market is set to reach a valuation of $1.82 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.5%. The anticipated growth during this period stems from ongoing advancements in research and drug creation, a surge in patient-focused healthcare approaches, the incorporation of precision medicine into clinical settings, improved availability of targeted treatments, and enhanced genomic profiling capacities. Key trends shaping the forecast horizon encompass increased cooperation in research and development, technological progress in diagnostics, joint research initiatives and clinical trials, a heightened emphasis on early diagnosis and detection, and the investigation of combination therapy options.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

What Are The Key Drivers Of Growth In The Gastrointestinal Stromal Tumor Market?

The escalating incidence of stomach cancer is anticipated to propel the future growth of the gastrointestinal stromal tumor market. Stomach cancer is defined by the unrestrained growth and multiplication of malignant cells within the stomach’s inner lining. While gastrointestinal stromal tumors (GISTs) can develop in the stomach, they are distinct from stomach cancer. It has been observed that patients with GISTs face an elevated risk of developing additional cancers, including small bowel adenocarcinoma, particularly when two separate tumors merge. As an illustration, the American Cancer Society, a US-based professional organization, stated in January 2024 that approximately 26,890 new cases of stomach cancer and 10,880 deaths are projected in the U.S. for 2024, representing 1.5% of all new cancer diagnoses. Therefore, the increasing occurrence of stomach cancer is fueling the expansion of the gastrointestinal stromal tumor market.

How Is The Gastrointestinal Stromal Tumor Market Classified Into Different Segments?

The gastrointestinal stromal tumormarket covered in this report is segmented –

1) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types

2) By Indication: Stomach; Small Intestine; Others Indications

3) By End-User: Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End-Users

Subsegments:

1) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy Regimens

2) By Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Agents

3) By Other Treatment Types: Surgery; Radiation Therapy; Clinical Trials For Novel Therapies

Which Market Trends Are Creating New Opportunities In The Gastrointestinal Stromal Tumor Industry?

Major companies engaged in the gastrointestinal stromal tumor market are developing new medications such as QINLOCK (Ripretinib) to serve larger client bases, generate more sales, and enhance revenue. QINLOCK (Ripretinib) is a prescribed drug utilized for treating advanced gastrointestinal stromal tumor (GIST). For instance, in January 2024, according to the US Food and Drug Administration (FDA), a federal agency based in the US, the CDER novel drug approvals stood at 37 in 2022, increasing to 55 drugs in 2023. CDER reported that 20 out of the 55 novel drugs (36%) approved in 2023 were first-in-class.

Who Are The Core Companies Influencing The Gastrointestinal Stromal Tumor Market Landscape?

Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

How Is Gastrointestinal Stromal Tumor Market Demand Varying Across Different Regions?

North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Gastrointestinal Stromal Tumor Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Stromal Tumor Market 2025, By The Business Research Company

Tumor Ablation Therapy Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

Tumor Embolization Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

Cancer Tumor Profiling Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Gastrointestinal Stromal Tumor Market Size Changed, over the years?

The market for gastrointestinal stromal tumor has seen robust growth in the past few years, from $1.28 billion in 2024, it is projected to reach $1.37 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.2%. The growth in the historical period is credited to the heightened awareness and early detection, advent of targeted therapies, improvement of surgical methods, advancement in personalized medicine, and betterment in supportive care.

How Much Will the Gastrointestinal Stromal Tumor Market Be Worth in 2029?

In the upcoming years, the size of the gastrointestinal stromal tumor market is anticipated to experience substantial growth, reaching a valuation of $1.82 billion in 2029 at a CAGR of 7.4%. Factors contributing to growth during this period include persistent efforts in research and drug development, a surge in patient-oriented healthcare, the incorporation of precision medicine into clinical procedures, an increase in the accessibility to targeted therapies, and an expansion in genomic profiling abilities. Noteworthy trends during this forecasted period encompass growing partnerships in research and development, enhancements in diagnostic technologies, cooperative research and clinical trials, a heightened emphasis on early detection and diagnosis, and an exploration of combined therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

Which is the Largest Company in the Gastrointestinal Stromal Tumor Market?

Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

What Are the Main Market Drivers in the Gastrointestinal Stromal Tumor Industry?

The incidence of stomach cancer is on the rise, which is anticipated to fuel the expansion of the gastrointestinal stromal tumor market. Stomach cancer is characterized by the unchecked growth of malignant cells within the stomach lining. Although gastrointestinal stromal tumors (GISTs) can also occur within the stomach, they should not be conflated with stomach cancer. Interestingly, patients with GISTs have a predisposition to contract extra cancers whenever two separate tumors collide and fuse into one. This includes cancers such as small bowel adenocarcinoma. For example, the American Cancer Society estimates that come January 2024, there will be approximately 26,890 new stomach cancer cases as well as 10,880 deaths in the U.S. alone. This constitutes 1.5% of all new cancer diagnoses for that year. Consequently, the expanding incidence of stomach cancer is propelling the growth of the gastrointestinal stromal tumor market forward. With the surge in demand for precision medicine, the gastrointestinal stromal tumor market is expected to experience significant growth. Precision medicine focuses on individualized healthcare decisions, interventions, and therapies which take into account each patient’s distinct genetic and lifestyle factors. Precision medicine for gastrointestinal stromal tumors involves molecular profiling to pinpoint specific mutations. This helps direct targeted therapies such as imatinib, which enhances the effectiveness of treatment methods and reduces side effects through individualized intervention. For example, the Personalized Medicine Coalition (PMC) reported in February 2023 that personalized medicines were responsible for 35% of the newly approved NMEs in 2021. With an additional 12 new approvals in 2022, personalized medicines have consistently accounted for at least a quarter of all new drug approvals over the past eight years, which is a considerable increase from less than 10% ten years ago. Thus, the burgeoning demand for precision medicine is stimulating the growth of the gastrointestinal stromal tumor market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp

How Is the Gastrointestinal Stromal Tumor Market Segments Structured?

The gastrointestinal stromal tumor market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types

2) By Indication: Stomach, Small Intestine, Others Indications

3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users

Subsegments:

1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens

2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents

3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies

What Strategic Trends Are Transforming the Gastrointestinal Stromal Tumor Market?

Leading businesses in the gastrointestinal stromal tumor industry are developing novel drugs such as QINLOCK (Ripretinib) to expand their customer reach, accelerate sales, and boost revenue. QINLOCK (Ripretinib) is a prescribed medication for advanced gastrointestinal stromal tumor (GIST). For instance, in January 2024, the US Food and Drug Administration (FDA), an American federal agency, reported that the CDER novel drug approvals increased from 37 in 2022 to 55 in 2023. From these 55 novel drugs approved in 2023, CDER classified 20 of them (or 36%) as first-in-class.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Which Global Regions Offer the Highest Growth in the Gastrointestinal Stromal Tumor Market?

North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13248

This Report Delivers Insight On:

1. How big is the gastrointestinal stromal tumor market, and how is it changing globally?

2. Who are the major companies in the gastrointestinal stromal tumor market, and how are they performing?

3. What are the key opportunities and risks in the gastrointestinal stromal tumor market right now?

4. Which products or customer segments are growing the most in the gastrointestinal stromal tumor market?

5. What factors are helping or slowing down the growth of the gastrointestinal stromal tumor market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the gastrointestinal stromal tumor industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has The Gastrointestinal Stromal Tumor Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

The market for gastrointestinal stromal tumors has seen significant growth in the past few years. It is projected to expand from $1.28 billion in 2024 up to $1.37 billion in 2025, at a compound annual growth rate (CAGR) of 7.2%. The notable growth during the historical period is due to factors like boosted awareness and early detection, the arrival of targeted treatments, advanced surgical interventions, the evolution of personalized healthcare, along with improvements in supportive care._x000D_

_x000D_

The market for gastrointestinal stromal tumors is projected to witness robust expansion in the coming years, reaching an estimated value of $1.82 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 7.4%. This expansion during the forecast period can be credited to consistent research and drug development efforts, the surge in patient-focused healthcare, the implementation of precision medicine in clinical routines, enhanced access to specified therapies, and growing genomic profiling capabilities. Notable trends anticipated in the forecast timeframe encompass increasing partnerships in research and development activities, advancements in diagnostic technology, collective scientific research and clinical testings, heightened attention on early detection and diagnosis, and the investigation of combined therapy options._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp_x000D_

_x000D_

#Which Factors and External Forces Are Driving Demand in the Gastrointestinal Stromal Tumor Market?#_x000D_

The increasing number of stomach cancer cases is expected to push the gastrointestinal stromal tumor market’s growth. Stomach cancer is characterised by the uncontrollable growth and spread of malignant cells in the stomach’s lining. Although gastrointestinal stromal tumors (GISTs) can also occur in the stomach, these are not the same as stomach cancer. Patients with GISTs have been observed to have a higher risk of developing additional cancers, such as small bowel adenocarcinoma, when two distinct tumors collide and become one. For instance, the American Cancer Society predicted approximately 26,890 new stomach cancer cases and 10,880 deaths in the U.S. by January 2024, making up 1.5% of all new cancer diagnoses. This surge in stomach cancer incidence is thereby fuelling the expansion of the gastrointestinal stromal tumor market.

Driving Factors for the Gastrointestinal Stromal Tumor Market: Increasing Demand for Precision Medicine Propels Market Further

_x000D_

 

_x000D_

#Which Segments in the Gastrointestinal Stromal Tumor Offer the Most Growth?#_x000D_

The gastrointestinal stromal tumor market covered in this report is segmented –_x000D_

_x000D_

1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types_x000D_

2) By Indication: Stomach, Small Intestine, Others Indications_x000D_

3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens_x000D_

2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents_x000D_

3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the Gastrointestinal Stromal Tumor Market?#_x000D_

North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Which Cutting-Edge Market Trends Are Expected to Drive theGastrointestinal Stromal Tumor Market’s Growth?#_x000D_

Leading firms in the gastrointestinal stromal tumor market are pioneering the innovation of new drugs like QINLOCK (Ripretinib) with an aim to reach a wider customer base, boost sales, and augment revenues. QINLOCK (Ripretinib) serves as a prescribed medication used for the treatment of an advanced gastrointestinal stromal tumor (GIST). For example, data from the US Food and Drug Administration (FDA), a federal agency based in the US, reveals that the CDER novel drug approvals rose from 37 in 2022 to 55 in 2023, in January 2024. Further, CDER classified 20 out of the 55 novel drugs (36%) granted approval in 2023 as first-in-class._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Gastrointestinal Stromal Tumor Market?#_x000D_

A gastrointestinal stromal tumor (GIST) is a type of rare, non-epithelial tumor that originates in the gastrointestinal (GI) tract. These are most commonly developed in the stomach or the small intestine, but they can occur anywhere along the GI tract, from the esophagus to the rectum._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13248_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theGastrointestinal Stromal Tumor Market?

The surge in stomach cancer cases is projected to spur the expansion of the market for gastrointestinal stromal tumors. Stomach cancer involves the malignant, uncontrolled growth of cells in the stomach lining. Although gastrointestinal stromal tumors (GISTs) can manifest in the stomach, they are different from stomach cancer. Patients with GISTs have a higher likelihood of developing additional cancers like small bowel adenocarcinoma when two distinct tumors combine into one. As noted by the American Cancer Society, come January 2024, approximately 26,890 new instances of stomach cancer and 10,880 deaths are expected in the U.S. for 2024, making up 1.5% of all fresh cancer diagnoses. As such, the escalating occurrence of stomach cancer is bolstering the expansion of the gastrointestinal stromal tumor market. The increasing need for precision medicine is forecasted to fuel the advancement of the gastrointestinal stromal tumor market. Precision medicine offers a tailored healthcare approach that factors in the individual characteristics of patients, such as their genetic makeup and lifestyle, when formulating decisions, interventions, and therapies. Precision medicine applied to gastrointestinal stromal tumors employs molecular profiling to uncover specific mutations and direct targeted therapies such as imatinib. This enhances the efficacy of treatments and diminishes side effects through personalized interventions. As per a report issued in February 2023 by the Personalized Medicine Coalition (PMC), a nonprofit organization based in the US, personalized medicines made up 35% of all newly authorized NMEs in 2021. Despite attaining 12 new approvals in 2022, they have consistently held a share of at least a quarter of all new drug approvals in the last eight years, up from less than 10% ten years prior. As a result, the growing demand for precision medicine is driving the advancement of the gastrointestinal stromal tumor market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

#What is the Growth Potential of the Gastrointestinal Stromal Tumor Market, and How Will It Perform by 2034?

The market size of gastrointestinal stromal tumors has seen significant growth in recent years. Projected expansion is set from $1.28 billion in 2024 to $1.37 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. This growth during the historic period is linked to amplified awareness and early detection, the advent of specialized treatments, better surgical methods, the emergence of individualized medicine, and improvements in supportive care.

In the coming years, the market for gastrointestinal stromal tumors is predicted to experience robust growth. The market valuation is anticipated to reach $1.82 billion by the year 2029, displaying a compound annual growth rate (CAGR) of 7.4%. The progress expected over the forecast period is on account of factors such as sustained research and development of drugs, an increase in patient-centered healthcare, ongoing integration of precision medicine into clinics, enhanced accessibility to targeted therapies, and the growth of genomic profiling capabilities. The forecast period will also see notable trends like an increased collaboration in R&D, improvements in diagnostic technology, joint research and clinical tests, greater emphasis on early detection and diagnosis, and investigation into the use of combinatory therapies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13248

Which Cutting-Edge Market Trends Are Expected to Drive theGastrointestinal Stromal Tumor Market’s Growth?

Leading corporations in the gastrointestinal stromal tumor market are developing innovative drugs like QINLOCK (Ripretinib) to cater to a wider customer base, boost sales, and augment revenue. QINLOCK (Ripretinib) is a prescribed medication for the treatment of advanced gastrointestinal stromal tumor (GIST). For example, the US Food and Drug Administration (FDA), a federal institution based in the US, recorded that the number of novel drug approvals by the CDER surged from 37 in 2022 to 55 in 2023. Notably, out of the 55 new drugs approved in 2023, CDER categorized 20 (36%) as first-in-class.

What Are the Leading Market Players Impacting theGastrointestinal Stromal Tumor Market’s Growth Trend?

Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

How Are the Key Segments of the Gastrointestinal Stromal Tumor Market Driving Opportunities and Innovations?

The gastrointestinal stromal tumor market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types

2) By Indication: Stomach, Small Intestine, Others Indications

3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users

Subsegments:

1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens

2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents

3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theGastrointestinal Stromal Tumor Market?# Market Expansion?

North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Gastrointestinal Stromal Tumor Market 2025, By The Business Research Company:

Intratumoral Cancer Therapies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report

Solid Tumor Cancer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

Circulating Tumor Cells Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: